Bluewater Group

Blue Water Biotech is a clinical-stage biotechnology company focused on developing transformative vaccines and pharmaceutical products. The company utilizes its proprietary Norovirus Shell and Protrusion (S&P) platform to create versatile vaccine candidates targeting infectious diseases such as influenza, norovirus, and rotavirus. In addition to its vaccine pipeline, Blue Water Biotech has expanded into the commercial space with the acquisition of Entadfi, an FDA-approved treatment for benign prostatic hyperplasia (BPH). The company aims to address significant global health challenges through innovative delivery technologies and strategic asset acquisitions.